Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Phase 2 N=61 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Phase 2 N=151 Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Breast Cancer Prevention
Primary: Change in Breast Density at 6 Months — -5.45; -13.71 cm^3
Phase 4 N=256 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
Benign Breast Disease · Fibrocystic Disease of Breast · Fibroadenoma
Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants
Phase 2 N=25 Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Breast Cancer
Primary: Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months — -3.0 percentage of positive cells — p=<0.001
N/A N=10 Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
Invasive Breast Cancer
Primary: Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery — 10 participants
Phase 3 N=3,066 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Phase 2 N=16 Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Breast Cancer
Primary: Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole. — 4 participants
Phase 2 N=67 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Phase 3 N=672 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Advanced Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — 23.8; 13.0 Months — p=<0.0000001
Phase 2 N=1,075 Green Tea and Reduction of Breast Cancer Risk
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 2 N=180 Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Stage 0 Breast Cancer AJCC v6 and v7 · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change
N/A N=266 Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Breast Cancer
Primary: Change in Absolute Breast Density — 65.53; 64.39; 65.08; 56.35 cm squared
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 3 N=2,672 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 87.3; 91.1 percentage of participants — p=.0002
Phase 2 N=49 Letrozole in Preventing Breast Cancer in Postmenopausal Women
Breast Cancer
Primary: Change in Lumbar Density From Baseline to 12 Months — -0.036; -0.021 g/cm^2 — p=0.15
Phase 2 N=92 Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
Breast Cancer · Breast Cancer, Early-Onset
Primary: Change in Proliferative Index (Ki67 Expression) — -14.5; -10.0 Difference from baseline (%) — p=0.002
Phase 2 N=199 LY353381 in Preventing Breast Cancer in Women With Hyperplasia
Breast Cancer
Primary: Change in Masood Score — -1.1; -0.8 units on a scale
N/A N=196 Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
Metastatic Breast Cancer
Primary: Real World Tumor Response (rwTR) of All Participants (Adjusted by Normalized Inverse Probability of Treatment Weighting [nIPTW]) — 52.1; 46.2 Percentage of Participants
Phase 2 N=36 Breast Cancer Risk Biomarkers in Premenopausal Women
Breast Cancer
Primary: The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day — 0.94 proportion of enrolled participants